NCT02631174View on ClinicalTrials.gov

Evaluation Of The Pharmacokinetics Of Antithrombin III In Neonates And Infants Undergoing CPB And ECMO Support

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

June 30, 2018

Study Completion Date

June 30, 2018

Conditions
Extracorporeal Membrane Oxygenation ComplicationCardiopulmonary Bypass
Interventions
DRUG

Antithrombin III

We are comparing neonates and infants on ECMP or CPB receiving ATIII, the dose of which is calculated to account for circuit volume, and compared with those not accounting for circuit volume

Trial Locations (1)

45229

Cincinnati Childrens Hospital Medical Center, Cincinnati

All Listed Sponsors
collaborator

Grifols Biologicals, LLC

INDUSTRY

lead

Children's Hospital Medical Center, Cincinnati

OTHER

NCT02631174 - Evaluation Of The Pharmacokinetics Of Antithrombin III In Neonates And Infants Undergoing CPB And ECMO Support | Biotech Hunter | Biotech Hunter